• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Long-term use of rituximab associated with lower rates of AAV relapse

byThomas SuandDeepti Shroff Karhade
June 1, 2020
in Chronic Disease, Nephrology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial involving patients with antineutrophil cytoplasmic antibody-associated vasculitis in complete remission, administration of rituximab for an additional 18 months was associated with a lower likelihood of relapse versus placebo.

2. Although the vast majority of patients in both groups reported at least 1 adverse event, major relapse-free survival was 100% in the treatment group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Current FDA recommendations for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) involve glucocorticoids and rituximab infusion therapy. While the MAINRITSAN (Maintenance of Remission Using Rituximab in Systemic ANCA-Associated Vasculitis) and MAINRITSAN2 trials clearly demonstrated the efficacy of rituximab in maintaining remission throughout the 18-month treatment period, nearly half of the patients went on to experience relapse within 3 years of discontinuation. This trial investigated the benefit of extending the treatment schedule for an additional 18 months, finding that none of the patients who continued to receive rituximab had a major relapse 28 months after re-randomization compared to 13% of the placebo group. No significant differences were observed in the incidence of minor relapse, the progression of organ damage, or quality of life. Adverse events and serious adverse events occurred at similar rates in both groups. The primary limitation of this study was that only patients who had completed the MAINRITSAN2 trial were eligible to be recruited, resulting in a relatively small and homogenous sample population. Nonetheless, the results of this study support the prolonged use of rituximab to prevent relapse in patients with AAV.

Click here to read the study, published today in Annals of Internal Medicine

Relevant Reading: Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis

In-Depth [randomized controlled trial]: In this multicenter, double-blind randomized control trial, 97 patients who completed the MAINRITSAN2 trial without any major relapses and were in complete remission according to the Birmingham Vasculitis Activity Score were randomly assigned in a 1:1 ratio to receive either biannual 500-mg rituximab infusions or placebo for 18 months. Of these patients, 68 had granulomatosis with polyangiitis and 29 had microscopic polyangiitis. At 28 months, relapse-free survival was 96% (95% CI, 91% to 100%) in the rituximab group versus 74% (95% CI, 63% to 88%) in the placebo group (hazard ratio, 7.5; P = 0.008). While 6 patients in the placebo group experienced major relapses (3 renal and 3 pulmonary flares), both relapses in the treatment group were minor. Antineutrophil cytoplasmic antibody (ANCA) positivity was observed in 50% of patients who had a relapse and only 15% of those who did not. Over 90% of patients in both groups had an adverse event of any severity, and infectious serious adverse events occurred in 12% of the treatment group and in 9% of the control group. At the end of the study, the rituximab group had a mean gamma globulin level of 6.6 g/L versus a concentration of 7.9 g/L in the placebo group (P < 0.001).

RELATED REPORTS

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antineutrophil cytoplasmic antibody-associated vasculitisGranulomatosis with polyangiitismicroscopic polyangiitisrituximab
Previous Post

Racial segregation linked with worse middle-age cognitive performance

Next Post

Rituximab found to reduce time to remission for myasthenia gravis

RelatedReports

#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
StudyGraphics

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

October 19, 2022
Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis
Chronic Disease

Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial

September 28, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Oncology

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

February 22, 2022
Next Post
Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis

Rituximab found to reduce time to remission for myasthenia gravis

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Natural language processing may automate data extraction from radiologic reports

Cultural, informational, and financial challenges associated with behavioral health integration

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options